Trials / Recruiting
RecruitingNCT05720117
A Study of PYX-201 in Advanced Solid Tumors
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- Sponsor
- Pyxis Oncology, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PYX-201 | Antibody-Drug Conjugate |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2026-07-01
- Completion
- 2027-05-01
- First posted
- 2023-02-09
- Last updated
- 2026-03-20
Locations
29 sites across 4 countries: United States, Belgium, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05720117. Inclusion in this directory is not an endorsement.